Background: Local high-intensity focused ultrasound (HIFU) is a minimally i
nvasive method of coagulation (85 degrees C) that ablates prostatic tissue
with high precision.
Patients and Methods: Over a 3-year period, 184 patients with organ-confine
d prostate cancer have undergone 232 sessions of transrectal HIFU therapy (
mean duration 90 minutes) under spinal anesthesia at 2.25 or 3.0 MHz, 50 W,
with a penetration depth of 25 mm,
Results: Follow-up sextant biopsies (mean 1.9) were cancer free in 80% of p
atients, and in patients with residual cancer, the tumor mass was reduced m
ore than 90%. The nadir value of prostate specific antigen (PSA) was <4 ng/
mL in 97%, including 61% who had values < 0.5 ng/mL. After primary HIFU, no
severe side effects (fistula, grade 2 or 3 incontinence, rectal mucosal bu
rn) were seen. All patients had a suprapubic tube (mean 29 days), and 33% n
eeded transurethral resection of debris (mean 7 g), Hospital discharge was
within 23 hours after treatment.
Conclusion: Transrectal HIFU enables minimally invasive local prostate tiss
ue ablation with high rates of negative biopsies, low PSA nadir, and low co
mplication rate, Further follow-up is needed to define the efficacy of dise
ase control.